| Literature DB >> 36263107 |
Dong-Hyuk Cho1, Jung-Woo Son1, Chan Joo Lee2, Jimi Choi3, Mi-Na Kim4, Ju-Hee Lee5, Sunki Lee6, Dong Heon Yang7, Hyun-Jai Cho8, Jin-Oh Choi9, Eung Ju Kim10, Dong-Ju Choi11, Byung-Su Yoo1.
Abstract
Several surrogate biomarkers possess prognostic significance for heart failure (HF), and a decline in their respective values may predict clinical improvement. However, data on the prognostic value of these biomarkers during short-term follow-up after discharge in acute decompensated HF are scarce. We aim to evaluate the prognostic value of short-term follow-up of surrogate biomarkers for predicting the prognosis of hospitalized patients with acute decompensated HF. This multi-center, prospective study will enroll consecutive hospitalized patients with acute decompensated HF. All patients will undergo sampling and comparison of biomarkers, including plasma N-terminal pro-brain natriuretic peptide, growth differentiation factor 15, troponin-T, high-sensitivity C-reactive protein, and urinary albumin/creatinine ratio obtained within 1 month and 6 months after discharge from the index admission. The primary endpoint is a composite of cardiovascular mortality or HF hospitalization during 1 year of follow-up. We will investigate the prognostic value of multiple biomarkers for the primary endpoint. This trial will provide robust evidence for novel multi-biomarker strategies for acute decompensated HF in real-world settings. Trial Registration: ClinicalTrials.gov Identifier: NCT04437628.Entities:
Keywords: Biomarkers; Heart failure
Year: 2022 PMID: 36263107 PMCID: PMC9383348 DOI: 10.36628/ijhf.2022.0005
Source DB: PubMed Journal: Int J Heart Fail ISSN: 2636-154X